🔍

JUBLINGREA - Jubilant Ingrev.

📊 NSE: JUBLINGREA 🏢 Chemicals 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

Jubilant Ingrevia faces GST demand and penalty of ₹2.04 crore for FY 2017-18

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 05 May 2026, 04:08 PM

Jubilant Ingrevia Limited has received an appeal order from the Additional Commissioner of State Tax, Moradabad, confirming a GST demand for the financial year 2017-18. The order includes a tax demand of ₹1.02 crore and an equivalent penalty of ₹1.02 crore, totaling approximately ₹2.04 crore plus applicable interest. The dispute centers on the alleged wrong availment and utilization of Transitional Input Tax Credit. The company plans to contest this order by filing an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).

Total confirmed demand of ₹2.04 crore, comprising ₹1.02 crore tax and ₹1.02 crore penalty.
The order relates to alleged violations regarding Transitional Input Tax Credit for FY 2017-18.
Company is in the process of filing an appeal before the GSTAT against the impugned order.
Management states there is no material financial or operational impact on the company's activities.

💡 Investors need not worry as the demand amount is not material relative to the company's balance sheet. Monitor for updates regarding the GSTAT appeal outcome.

Jubilant Ingrevia Schedules Q4 & FY26 Earnings Conference Call for May 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Apr 2026, 07:46 PM

Jubilant Ingrevia Limited has announced that it will host its earnings conference call on May 26, 2026, at 5:00 PM IST. The call is intended to discuss the audited financial results for the fourth quarter and the full fiscal year ended March 31, 2026. The management team will provide a brief discussion on financial performance followed by a Q&A session. This is a standard procedure for the company to engage with analysts and institutional investors following its annual results filing.

Conference call scheduled for May 26, 2026, at 5:00 PM IST following result submission.
Company manages a portfolio of 130+ products across Specialty Chemicals and CDMO segments.
Operations include 50 plants across 5 manufacturing facilities in India with 2,300+ employees.
R&D infrastructure consists of 3 centers employing 150 scientists for cutting-edge innovation.

💡 Investors should monitor the financial results release on May 26 and attend the call to understand management's outlook on the CDMO business and specialty chemical margins. Key focus areas should be the performance of the Vitamin-B3 and Acetyls segments.

Jubilant Ingrevia Clarifies No Material Information Behind Recent Stock Price and Volume Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Apr 2026, 01:47 PM

Jubilant Ingrevia Limited has responded to a clarification request from the National Stock Exchange (NSE) regarding a recent significant spurt in trading volume and price movement. The company officially stated that there is no material unpublished price-sensitive information (UPSI) that has not been disclosed to the exchanges. This clarification follows a surveillance inquiry (Ref. No.: NSE/CM/Surveillance/16903) dated April 22, 2026. The company maintains that it is in full compliance with SEBI (LODR) Regulations, 2015.

NSE issued a clarification request on April 22, 2026, regarding unusual market activity.
Company responded on April 23, 2026, denying any undisclosed material developments.
The inquiry was triggered by a significant spurt in trading volume and price volatility.
Company reaffirmed commitment to disclose all price-sensitive information as per SEBI regulations.

💡 Investors should note that the recent price movement is likely market-driven rather than based on internal company developments. Exercise caution and avoid trading based on speculative rumors given the company's official denial of undisclosed news.

Jubilant Ingrevia Grants 3.43 Lakh Stock Options to Employees at Re 1 Exercise Price

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Apr 2026, 05:57 PM

Jubilant Ingrevia has approved the grant of 3,43,569 stock options to eligible employees under its 2021 ESOP plan. The grant is divided into 2,40,497 performance-linked options and 1,03,072 tenure-linked options, both with an exercise price of Re 1. These options are designed for long-term retention, with a vesting schedule set for after the FY30 financial closure. The performance-linked portion is contingent upon both company-wide parameters and individual performance ratings.

Grant of 3,43,569 stock options representing equity shares of Re 1 face value each
Includes 2,40,497 performance-linked options and 1,03,072 tenure-linked options
Exercise price is set at the face value of Re 1 per share
Vesting is scheduled for after the FY30 financial closure, ensuring long-term commitment
Options must be exercised within one year from the date of vesting

💡 This is a routine administrative update regarding employee compensation and retention. No immediate action is required as it does not significantly impact the company's current financial standing or share price.

Jubilant Ingrevia: Promoter Group Files Annual No-Encumbrance Declaration

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Apr 2026, 12:40 PM

The Hari Shanker Bhartia Family Trust, representing the promoter group of Jubilant Ingrevia Limited, has filed its annual disclosure under Regulation 31(4) of SEBI (SAST) Regulations. This mandatory filing confirms that the promoters have not created any encumbrance or pledge on their shareholding, directly or indirectly, during the financial year. This is a routine compliance procedure that ensures transparency regarding the stability of promoter equity. The declaration provides assurance to investors that promoter shares remain free of any liens or debt-related obligations.

Annual disclosure submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Declaration made by Hari Shanker Bhartia Family Trust on behalf of the promoter group
Confirms that no shares held by the promoter group were pledged or encumbered during the fiscal year
Standard regulatory compliance ensuring transparency in promoter shareholding patterns

💡 No action is required as this is a routine regulatory filing confirming the absence of promoter share pledges. It reflects a stable promoter holding which is generally a positive sign for long-term investors.

Jubilant Ingrevia Completes 100% Acquisition of Remidex Pharma Private Limited

🟢 POSITIVE ⭐ 8/10

M&A 📅 30 Mar 2026, 06:30 PM

Jubilant Ingrevia Limited has successfully finalized the acquisition of a 100% equity stake in Remidex Pharma Private Limited. This transaction follows the initial Share Purchase Agreement announced on March 13, 2026. The acquisition was completed on March 30, 2026, effectively making Remidex a wholly-owned subsidiary of the company. This move aligns with the company's strategic growth objectives in the pharmaceutical and chemical ingredients space.

Acquired 100% equity stake in Remidex Pharma Private Limited
Transaction completed on March 30, 2026, at 6:05 PM IST
Follows the initial disclosure and agreement dated March 13, 2026
Remidex Pharma is now a wholly-owned subsidiary of Jubilant Ingrevia

💡 Investors should view this as a positive step toward inorganic growth and monitor the integration's impact on consolidated margins. Watch for further details on synergy benefits in the next quarterly earnings call.

Jubilant Ingrevia to Close Trading Window from April 1, 2026 for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Mar 2026, 07:56 PM

Jubilant Ingrevia Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI insider trading regulations. This closure is a standard procedure ahead of the declaration of the company's audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. The window will remain closed for all designated persons and will reopen 48 hours after the results are officially disclosed to the stock exchanges. The specific date for the board meeting to approve these results has not yet been finalized and will be communicated later.

Trading window closure effective from Wednesday, April 01, 2026.
Closure pertains to the Audited Standalone & Consolidated Financial Results for FY ending March 31, 2026.
Window to remain closed until 48 hours after the financial results are announced.
Designated persons are prohibited from trading in company securities during this period.

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should focus on the upcoming earnings release to assess the company's financial health and growth trajectory.

Jubilant Ingrevia Starts Commercial Production of Agro Intermediate at Bharuch Site

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 21 Mar 2026, 06:43 PM

Jubilant Ingrevia's wholly-owned subsidiary, Jubilant Agro Sciences Limited, has officially commenced commercial production of an Agro Intermediate at its Bharuch facility. This production is part of a strategic CDMO contract with a leading global agrochemical company. The company confirmed that the dispatch of materials has already begun as of March 21, 2026. This development marks a significant milestone in the company's specialty chemicals and CDMO growth trajectory.

Commencement of commercial production of Agro Intermediate at the Bharuch site on March 21, 2026
Production is linked to a specific CDMO contract with a leading global Agrochemical Company
Immediate dispatch of materials started on the same day as the announcement
Executed through wholly-owned subsidiary Jubilant Agro Sciences Limited

💡 Investors should monitor the upcoming quarterly results for the revenue contribution from this new production line. This development strengthens the company's position in the high-margin CDMO segment and validates its execution capabilities.

Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore

🟢 POSITIVE ⭐ 7/10

M&A 📅 13 Mar 2026, 08:18 PM

Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.

Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.
Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.
Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.
Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.
The acquisition is expected to be finalized within an indicative period of 30 days.

💡 Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.

Jubilant Ingrevia Seeks Re-appointment of Independent Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Mar 2026, 08:10 PM

Jubilant Ingrevia Limited has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mrs. Ameeta Chatterjee as an Independent Director. The proposed re-appointment is for a second term of five years, effective from April 17, 2026, to April 16, 2031. Shareholders eligible as of the February 26, 2026, cut-off date can participate in the remote e-voting process. The voting results will be declared on or before April 7, 2026.

Proposal for re-appointment of Mrs. Ameeta Chatterjee as Independent Director for a second 5-year term.
The new term is scheduled to run from April 17, 2026, until April 16, 2031.
Remote e-voting period starts March 6, 2026, and ends April 4, 2026.
The cut-off date for shareholder eligibility to vote was February 26, 2026.
The resolution is being proposed as a Special Resolution requiring requisite majority approval.

💡 This is a routine corporate governance matter regarding board composition. Investors should review the director's profile in the explanatory statement and cast their votes during the e-voting window.

Jubilant Ingrevia receives ₹72.1 Lakh Tax Demand and Penalty for FY 2017-18

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 09 Feb 2026, 04:52 PM

Jubilant Ingrevia Limited has received an order from the Assistant Commissioner of Central GST, Bijnor, confirming a demand for Service Tax on Ocean Freight for the financial year 2017-18. The total demand consists of ₹36.05 lakh in tax and an equivalent penalty of ₹36.05 lakh, plus interest. The company has stated it has a strong case on merits and intends to file an appeal before the Commissioner (Appeals). Management has clarified that this development will not have any material financial or operational impact on the company.

Tax demand of ₹36,04,971 confirmed for FY 2017-18 regarding Ocean Freight
Penalty of ₹36,04,971 imposed by the CGST authorities
Interest charges applicable under Section 75 of the Finance Act, 1994
Company to file an appeal before the Commissioner (Appeals) upon receipt of the certified order
Management confirms no material financial or operational impact on the entity

💡 No immediate action is required as the financial impact is negligible relative to the company's scale. Investors should view this as a routine tax litigation matter.

Jubilant Ingrevia Q3 FY26: 9% Volume Growth, INR 2.5 Interim Dividend, EBITDA at INR 136 Cr

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 04:42 PM

Jubilant Ingrevia reported stable Q3 FY26 revenue of INR 1,051 crore, supported by a 9% year-on-year volume growth that offset softer global pricing. The company declared an interim dividend of 250% (INR 2.5 per share) and highlighted a robust opportunity funnel of over 100 projects with a peak revenue potential of INR 3,500 crore. While quarterly EBITDA dipped 8% to INR 136 crore due to pricing headwinds, the 9-month EBITDA rose 8% to INR 436 crore. Management expects growth to accelerate in Q4 FY26, driven by the commencement of a major CDMO order and new capacity expansions.

Achieved 9% YoY volume growth in Q3 FY26, marking the second-highest volumes in the last 12 quarters.
Declared an interim dividend of 250%, translating to INR 2.5 per equity share.
Specialty Chemicals segment maintained resilient margins above 25% despite intense global pricing pressure.
Secured 16 new molecule wins during the year with an estimated peak revenue potential of INR 1,400 crore.
Renewable energy share increased to 34%, contributing to a 10% YoY reduction in power and fuel expenses.

💡 Investors should focus on the company's transition toward high-margin CDMO and specialty segments, with Q4 FY26 being a critical period for new order execution. The stock is a 'Watch' for signs of recovery in global chemical pricing which could further boost EBITDA margins.

Jubilant Ingrevia Releases Audio Recording of Q3 FY26 Investor Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 07:25 PM

Jubilant Ingrevia Limited has disclosed the audio recording link for its investor conference call held on February 5, 2026. The call addressed the company's unaudited financial performance for the quarter and nine-month period ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording on the company's website to hear management's detailed commentary on business operations and future outlook.

Audio recording for Q3 and 9M FY26 earnings call is now publicly available.
The conference call was conducted on February 5, 2026, following the results announcement.
Filing made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Recording provides access to management's responses to institutional investor queries.

💡 Investors should listen to the recording to understand management's guidance on margins and demand trends in the specialty chemicals sector. No immediate action is required as this is a routine procedural filing.

Jubilant Ingrevia Publishes Q3 & 9M FY26 Financial Results in Newspapers

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 05 Feb 2026, 04:52 PM

Jubilant Ingrevia Limited has published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Board of Directors on February 4, 2026, and subsequently advertised in Financial Express and Hindustan newspapers on February 5, 2026. This filing is a routine regulatory requirement under SEBI (LODR) Regulations to ensure public access to financial performance data. Investors can access the full results via the company's website or the provided QR code in the advertisements.

Board of Directors approved Q3 and nine-month results on February 4, 2026
Results published in Financial Express (English) and Hindustan (Hindi) on February 5, 2026
Filing includes a Quick Response (QR) code for direct digital access to financial statements
Compliance maintained with Regulations 30 and 47 of SEBI (LODR) Regulations, 2015

💡 Investors should review the detailed financial statements on the company website to evaluate the quarterly performance metrics. This is a procedural filing and does not contain new financial data beyond what was previously approved by the board.

Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:48 PM

Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.

Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.
Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.
CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.
The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.
Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.

💡 Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.

View All JUBLINGREA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Specialty Chemicals (SC) grew 15% YoY in FY25 to INR 1,818 Cr and 12% YoY in Q2 FY26. Nutrition & Health Solutions (NHS) reported INR 181 Cr in Q2 FY26, a 1% QoQ increase but 1% YoY decline. Chemical Intermediates (CI) achieved its highest quarterly revenue in 6 quarters in Q2 FY26 despite pricing pressures.

Geographic Revenue Split

Domestic India accounts for 53% of revenue. International markets contribute 47%, with Europe and Japan at 29%, and China/Rest of World at 18%. US revenue grew significantly by 52% YoY in FY25.

Profitability Margins

Standalone Profit After Tax (PAT) was INR 251.2 Cr in FY25, up 37% YoY with a 6.0% margin. Q2 FY26 PAT grew 18% YoY to INR 70 Cr. Operating margins are expected to sustain at 13-15% over the medium term as the product mix shifts toward higher-margin SC and NHS segments.

EBITDA Margin

Consolidated EBITDA margin improved to 12.4% in FY25 from 10.2% in FY24. Specialty Chemicals achieved a record 27% margin in Q4 FY25 and maintained 26% in Q2 FY26. Overall EBITDA grew 8% YoY in Q2 FY26 and 18% in H1 FY26.

Capital Expenditure

The company incurred INR 1,800 Cr in capex between FY22 and FY25. Planned capex for FY26 is approximately INR 600 Cr, primarily for the CDMO Agro plant at Bharuch and a new multipurpose facility at Gajraula.

Credit Rating & Borrowing

Crisil reaffirmed 'Crisil A1+' for commercial paper. India Ratings affirmed 'IND AA+/Stable/IND A1+' for bank loan facilities of INR 2,388.38 Cr. Interest coverage ratio improved to ~10 times in FY25 from 8.67 times in FY24.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (for Acetyls/CI segment), Pyridine, and Picolines. The company is significantly backwards integrated in Pyridine and Picolines, which supports its cost leadership in Specialty Chemicals.

Import Sources

China is mentioned as a historical source and a competitor region; the company has de-risked its Pyridine exposure to China by entering other geographies like Europe and Japan.

Capacity Expansion

Groundbreaking of a new Multi-Purpose Plant (MPP) in Gajraula is underway with completion expected by late 2026. A new CDMO Agro plant is also being commissioned at Bharuch to serve a major USD 300M+ contract.

Raw Material Costs

Raw material costs are impacted by global pricing volatility; however, vertical integration in Pyridine and Acetyls helps mitigate these fluctuations. Lean 1.0 initiatives delivered INR 120 Cr in annualised savings.

Manufacturing Efficiency

Lean 2.0 has been launched to deliver an additional INR 100 Cr+ in annualised cost savings in FY26. The company focuses on digitising operations to maintain cost leadership.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

The 'Pinnacle 345' plan aims to triple revenue and quadruple EBITDA in 5 years. This will be achieved through a USD 300M+ 5-year CDMO contract starting in early 2026, entry into high-tech semiconductor chemicals with a new R&D facility in Greater Noida, and expanding Diketene derivative capacities.

Products & Services

Pyridine, Picolines, Diketene derivatives, Acetic Anhydride, Ethyl Acetate, Vitamin B3 (Niacinamide), Choline Chloride, and CDMO services for agrochemical and pharmaceutical innovators.

New Products/Services

New product launches include high-purity semiconductor chemicals and expanded human nutrition solutions. The CDMO segment has a funnel of 100+ new opportunities.

Market Expansion

Targeting increased export share (currently 47%) and deeper penetration in the US market, which saw 52% growth in FY25. Entry into the semiconductor innovation space via the Greater Noida R&D facility.

Market Share & Ranking

Global leadership in pyridine derivatives and a leading market position across most core products.

Strategic Alliances

Signed a USD 300+ million, five-year CDMO contract with a leading multinational agrochemical innovator.

🌍 External Factors

Industry Trends

The industry is seeing a steady recovery in volumes but pricing remains under pressure. There is a shift toward sustainable 'green' chemical variants and increased outsourcing to CDMOs (market projected to reach USD 319.6 billion by 2029).

Competitive Landscape

Competes with global players and Chinese manufacturers. European competitors are currently disadvantaged by elevated energy costs and weaker demand.

Competitive Moat

Moat is built on deep vertical integration (Pyridine/Acetyls), cost leadership through Lean initiatives, and high switching costs in the CDMO segment due to regulatory and technical complexity.